Pro108Ser mutation of SARS-CoV-2 3CL^pro reduces the enzyme activity and ameliorates the clinical severity of COVID-19.

ABSTRACT: Recently, an international randomized controlled clinical trial showed that patients with SARS-CoV-2 infection treated orally with the 3-chymotrypsin-like protease (3CL^pro) inhibitor PF-07321332 within three days of symptom onset showed an 89% lower risk of COVID-19-related hospital admission/ death from any cause as compared with the patients who received placebo. Lending support to this critically important result of the aforementioned trial, we demonstrated in our study that patients infected with a SARS-Cov-2 sub-lineage (B.1.1.284) carrying the Pro108Ser mutation in 3CL^pro tended to have a comparatively milder clinical course (i.e., a smaller proportion of patients required oxygen supplementation during the clinical course) than patients infected with the same su

SUBMITTER: Abe K 

PROVIDER: S-EPMC8789791 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature